Thermo King

The future is colder: pharma cold chain in the age of mRNA vaccines

“It’s plausible that Europe is moving toward a kind of pandemic end game”. So said Hans Kluge, of the World Health Organization’s (WHO), amid suggestions the Omicron variant could infect 60% of Europeans by March 2022 – and result in broad group immunity.

But what of lower income regions? On the face of it, progress here has also been impressive, with GAVI reporting that 1 billion doses have already been distributed by COVAX to 144 countries – with AVAT and COVAX hoping to secure 720 million doses to achieve 60% coverage in Africa by June 2022.

Yet in reality:

All this at a time when vaccine manufacture is close to 1.5 billion doses per month. That’s enough to ensure all targets are met, if equitable distribution is followed. Which is why the WHO has publicly stated: “This is not a supply problem; it’s an allocation problem”.

Reimagining the future

Central to this ‘allocation problem’ is a lack of ultra-low pharma cold chain maturity in lower income regions. It’s a pressing challenge too, considering the fragility of mRNA vaccines – where ultra-cold storage helps to slow down the chemical reactions that can tear them apart.

What’s more, the challenge is only set to get bigger as mRNA vaccines are applied to tackling other diseases – from cancer and flu, to malaria and HIV. It’s a technology that’s revolutionizing the pharmaceutical sector, and ushering in a new era of vaccinology.

Little wonder then that many are predicting the ‘future is colder”. And as key cold chain players like Maersk recognize, the opportunity now exists to reimagine “a pharmaceutical and healthcare supply chain ecosystem for the future”.

An end-to-end pharma cold chain

Inspiring any form of change however is a task steeped in complexity. That’s because most vaccines follow an intricate path from manufacturing plant to patient:

Existing solutions

Reimagining the pharma cold chain capabilities needed to optimize every stage of this process is therefore a vital step. But it’s important to recognize that such a move doesn’t involve a re-imagination of the technology involved. The pharmaceutical industry can already call upon advance solutions to help protect vaccine efficacy.

Leading the way in this regard are Thermo King Cold Storage Solutions, which provide the full package of refrigeration units and container designed exclusively for vaccine storage – with products that include:

Defining what’s needed

If the future is to be cold, then technology will clearly play a central role. Moving vaccines, maintaining GDP protocols, and demonstrating compliance, are tasks that help shape the qualities by which any equipment is judged. Particularly when deployed to less developed nations where the transport infrastructure alone presents unique challenges.

What are these values to judge by? Well, we’d suggest the following four as being critical:

Proven technology

Thermo King has worked closely with the pharmaceutical industry and world health bodies to support the Covid-19 vaccine roll-out. We’re confident that our end-to-end cold chain capabilities can help deliver true vaccine equity today – to any location.

You can find out more about our Cold Storage Solutions here.

Other relevant articles that might interest you

Marine

The future of food is fish.
With fish consumption expected to increase by 80% in the next two decades, we explain the key …

Marine

The future is colder: pharma cold chain in the age of mRNA vaccines.
The pharma cold chain plays a significant role in the distribution of mRNA vaccines, as it …

Marine

Thermo King Partners with Grindrod to Enable Temperature Control in their Refrigerated Containers.
Transporters moving perishable goods like grapes or citrus fruit throughout South Africa,can now benefit from …